ADVM trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ADVM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Adverum Biotechnologies, Inc. (ADVM) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $96M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, ADVM trades at a trailing P/E of -0.7x.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 OCGNOcugen, Inc. | $339M | $1.00 | $5.00 | +400.0% | Buy | — | 6 |
 EDITEditas Medicine, Inc. | $413M | $2.69 | $4.00 | +48.7% | Buy | — | 25 |
 KRYSKrystal Biotech, Inc. | $10.1B | $341.75 | $383.75 | +12.3% | Buy | 44.7x | 17 |
 RAREUltragenyx Pharmaceutical Inc. | $1.5B | $14.88 | $25.83 | +73.6% | Buy | — | 33 |
 BMRNBioMarin Pharmaceutical Inc. | $12.0B | $62.21 | $90.88 | +46.1% | Buy | 12.4x | 41 |
 SRPTSarepta Therapeutics, Inc. | $2.0B | $18.95 | $23.33 | +23.1% | Buy | 5.7x | 55 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.86 | +2.6% | Buy | 40.6x | 24 |
 RCKTRocket Pharmaceuticals, Inc. | $330M | $3.02 | $9.00 | +198.0% | Buy | — | 19 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.6B | $801.82 | $827.71 | +3.2% | Buy | 14.7x | 49 |
 IONSIonis Pharmaceuticals, Inc. | $7.3B | $43.93 | $86.25 | +96.3% | Buy | — | 33 |
Quick answers to the most common questions about buying ADVM stock.
The consensus price target for ADVM is $N/A, close to the current price of $4.36 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
ADVM has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
ADVM's current price is $4.36 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for ADVM, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
ADVM is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ADVM stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
ADVM appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ADVM analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.